Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
NCT04076761 · Sunnybrook Health Sciences Centre · PHASE2 · terminated · last registry update 2022-12-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Funding” | – | Registry record, Sunnybrook Health Sciences Centre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMP within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-03Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-11-03Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-09-18Also stopped (terminated): GERCOR - Multidisciplinary Oncology Cooperative Group, Trifluridine/Tipiracil + Oxaliplatin (NCT04894123)
- 2023-03-15Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, TAS 102 + Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA] (NCT03686488)
- 2023-02-22Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Trifluridine/tipiracil chemoradiation + Capecitabine based chemoradiation (NCT04177602)
- 2022-12-29Results posted on the registry: Academic and Community Cancer Research United, Binimetinib + Palbociclib (NCT03981614)
- 2022-10-31Phase 3 first posted: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
- 2022-09-23Also stopped (terminated): University of Wisconsin, Madison, TAS-102 + Temozolomide (NCT02943733)
- 2022-09-22Results posted on the registry: Mayo Clinic, Irinotecan + Irinotecan Hydrochloride (NCT04072445)
- 2022-04-14Phase 3 first posted: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2022-02-04Phase 3 first posted: Institut de Recherches Internationales Servier, Futuximab/modotuximab + Trifluridine/Tipiracil (NCT05223673)
- 2022-01-20Phase 3 first posted: Amgen, Sotorasib + Panitumumab (NCT05198934)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision